Pterostilbene: Resveratrol's Higher-Bioavailability Analogue — A Research-Backed Guide

What is pterostilbene?

Pterostilbene (pronounced tero-STIL-been) is a naturally occurring stilbene polyphenol first identified in Pterocarpus marsupium heartwood and later found in meaningful amounts in blueberries (~0.1–0.5 µg/g fresh weight), grapes, and a handful of other berries. Humans cannot obtain meaningful supplemental doses from diet alone — even a large serving of blueberries delivers only a few micrograms, not the milligrams used in research.

Chemically, pterostilbene is 3,5-dimethoxy-4'-hydroxystilbene. Its parent compound resveratrol has hydroxyl groups (-OH) at the 3 and 5 positions; pterostilbene replaces those with methoxy groups (-OCH₃). This seemingly minor change has major consequences for how the body processes the molecule.

In the body, pterostilbene is extensively metabolized but remains substantially bioavailable in its parent form. It induces phase II detoxification enzymes, activates SIRT1 (the "longevity sirtuin"), and modulates AMPK and Nrf2 — the same overlapping pathway cluster that has made resveratrol the focus of intense anti-aging research since the early 2000s.

How pterostilbene differs from resveratrol

The structural difference between pterostilbene and resveratrol creates three pharmacological advantages:

• Bioavailability: Resveratrol undergoes rapid conjugation (sulfation and glucuronidation) in the gut wall and liver, leaving only ~1% as free (unconjugated, pharmacologically active) resveratrol in plasma. Pterostilbene's methoxy groups sterically hinder this conjugation, yielding ~80% bioavailability in preclinical models and substantially higher plasma concentrations in humans per milligram ingested.
• CNS penetration: Methoxy groups increase lipophilicity, facilitating blood-brain barrier crossing. Rat studies show pterostilbene accumulates in hippocampal tissue at concentrations sufficient to activate cognitive-relevant signaling pathways. No comparable human brain-imaging data exist yet.
• Half-life: Pterostilbene has a longer plasma half-life (~105 minutes vs ~14 minutes for resveratrol), meaning twice-daily dosing maintains more stable plasma levels.

The tradeoff: resveratrol has a larger human clinical trial database (hundreds of published RCTs vs dozens for pterostilbene), and resveratrol has been the subject of high-profile longevity research from Sinclair's lab at Harvard. Pterostilbene is pharmacologically more efficient but clinically less documented.

Evidence-based benefits of pterostilbene

1. Antioxidant and anti-inflammatory activity

In preclinical models, pterostilbene is a potent activator of Nrf2, the master regulator of the cellular antioxidant response. This induces superoxide dismutase, catalase, and glutathione peroxidase — the body's endogenous antioxidant enzymes. A small 2013 human pilot (Riche et al., n=80, 8 weeks) found 50 mg twice daily did not significantly reduce systemic markers of oxidative stress in healthy overweight adults, tempering enthusiasm from animal studies. Anti-inflammatory effects in humans remain to be confirmed in adequately powered RCTs.

2. Cognitive performance

Animal data are compelling: aged rats given pterostilbene show improved spatial memory, enhanced hippocampal long-term potentiation, and reduced neuroinflammatory markers (Joseph et al.; Poulose et al.). The mechanistic rationale is strong — SIRT1 activation in the hippocampus is associated with improved synaptic plasticity, and brain-level pterostilbene concentrations are achievable in rodents at reasonable doses. However, human cognitive RCTs specific to pterostilbene are lacking. The Riche 2013 trial included cognitive measures but was not powered to detect changes. This remains the weakest link in the pterostilbene evidence chain.

3. LDL cholesterol reduction

The Riche 2013 randomized, double-blind trial (n=80, 8 weeks) remains the primary human data point. Both 50 mg/day and 100 mg/day pterostilbene significantly reduced LDL cholesterol compared to placebo (reductions of ~8–12 mg/dL). Interestingly, the 100 mg/day group showed a modest rise in blood pressure that the 50 mg/day group did not — a finding that has not been fully explained but warrants caution at higher doses. Total cholesterol and triglycerides were not significantly changed.

4. Blood glucose and insulin sensitivity

Multiple animal studies show pterostilbene activates AMPK in muscle and liver, improving glucose uptake and hepatic insulin sensitivity. In db/db diabetic mice, pterostilbene reduced fasting glucose to near-normal levels. Human data are limited to the Riche trial, which showed a non-significant trend toward lower fasting glucose. More adequately powered human studies in metabolic syndrome populations are needed before any glucose-lowering claim is justified.

5. SIRT1 activation and longevity pathways

Pterostilbene activates SIRT1 at concentrations more easily achieved in vivo than with resveratrol. SIRT1 is a NAD+-dependent deacetylase that regulates mitochondrial biogenesis, fat oxidation, inflammation, and stress resistance — the same pathways targeted by caloric restriction. While longevity research in humans is inherently difficult to conduct, the mechanistic rationale for pterostilbene as a sirtuin activator is stronger than for many compounds marketed for anti-aging purposes.

Supplement forms

How much pterostilbene should you take?

There is no established RDA or official upper limit for pterostilbene. Human trial experience is as follows:

• 50 mg/day (25 mg twice daily or 50 mg once): The lowest dose used in the principal human RCT. Showed LDL reduction without blood pressure signal. Best safety profile in current human data.
• 100 mg/day: Used in Riche 2013 with additional LDL benefit but a blood pressure increase signal. Use with caution if hypertensive.
• 150–250 mg/day: Sometimes used in practice based on animal-to-human dose conversion. No human RCT has formally evaluated this range for efficacy or safety.

Practical guidance: start with 50 mg/day with food. If pursuing cognitive or longevity goals, twice-daily dosing (50 mg AM + 50 mg PM with meals) maintains steadier plasma levels given the ~105-minute half-life. Do not exceed 250 mg/day in the absence of clinician guidance.

Safety and side effects

Pterostilbene has a favorable short-term safety profile in the limited human data available. The Riche 2013 trial found no serious adverse events at 50 or 100 mg/day over 8 weeks. Long-term safety data beyond 3 months in humans are essentially absent.

Potential concerns

• Blood pressure elevation at higher doses: The 100 mg/day group in Riche 2013 showed a statistically significant increase in blood pressure vs placebo. The mechanism is unclear. Monitor blood pressure if using doses above 50 mg/day, especially if hypertensive.
• Estrogenic activity: Like resveratrol, pterostilbene has mild phytoestrogenic properties in preclinical assays. Clinical significance at supplemental doses is unknown. People with hormone-sensitive conditions (breast cancer, uterine cancer, endometriosis) should consult their oncologist or gynecologist.
• Pregnancy and breastfeeding: No safety data exist. Avoid during pregnancy and lactation.
• Long-term unknowns: The compound has been in widespread supplemental use for less than two decades. Multi-year safety data from human trials are absent.

Drug and nutrient interactions

• Anticoagulants and antiplatelets (warfarin, aspirin, clopidogrel, apixaban, rivaroxaban) — pterostilbene inhibits platelet aggregation and may inhibit CYP2C9, the primary enzyme that metabolizes warfarin. Concomitant use increases bleeding risk. Requires prescriber consultation and INR monitoring if on warfarin.
• Statins — theoretical synergy for LDL reduction. No pharmacokinetic interaction documented, but additive LDL lowering could be an advantage or could be monitored for excessive reduction in frail patients.
• CYP enzyme substrates — pterostilbene inhibits CYP2B6 and CYP2C9 in vitro. Drugs with narrow therapeutic windows metabolized by these enzymes (phenytoin, warfarin, some NSAIDs) may have elevated plasma levels. Clinical significance unclear but warrants caution.
• Estrogen-containing therapies — mild additive estrogenic effect possible. Discuss with prescriber if taking HRT or oral contraceptives.
• NMN/NAD+ precursors — commonly co-supplemented; no pharmacokinetic interaction documented. The combination is based on mechanistic rationale rather than clinical trial evidence.

Check our free interaction checker for additional combinations.

Who might benefit — and who shouldn't

Frequently asked questions

Related ingredients and articles